Maine
The Board of Pharmacy held its regular meeting on November 7. The agenda includes second notice of rulemaking on prescribing, dispensing and administering HIV medicine.
For more information, please contact NACDS’ Mike Sargent at 207-272-6435.
Massachusetts
The Board of Registration in Pharmacy held its regular meeting on November 6. The agenda included the following:
- New pharmacy labeling requirement (Shield Law 2.0)
- Pharmacy Advisory Committee meeting summary
- Recommendation for automated non-sterile compounding devices
MassHealth provided notice via All Provider Bulletin 412 to all providers using 340B drugs that it will stop paying for the high-cost drugs listed in this most recent bulletin, in addition to those outlined in All Provider Bulletin 390 and All Provider Bulletin 400. This follows M.G.L. c. 118E, § 13L, 130 CMR 405.000: Community Health Centers, 130 CMR 406.000: Pharmacy Services and 130 CMR 410.000: Outpatient Hospital Services.
MassHealth will implement these changes no sooner than May 4, 2026, through a follow-up All Provider Bulletin. MassHealth is inviting comments about these changes no later than December 3. See All Provider Bulletin 412 for details.
For more information, please contact NACDS’ Mike Sargent at 207-272-6435.
Nebraska
The Board of Pharmacy posted an agenda for its November 17 meeting.
Also in Nebraska, the Department of Health and Human Services (DHHS), in partnership with the University of Nebraska Public Policy Center, has launched the Prevention & Care Provider Survey to find out more about care of certain infectious diseases in the state.
This anonymous online survey asks about your experiences and perspectives related to prevention, testing and diagnosis, patient care and services in Nebraska, with some questions asking about HIV in particular. Your input is critical for informing policies on HIV prevention and care across the state.
To access the survey, please visit: https://go.unl.edu/hiv-providersurvey or scan the QR code with a mobile device.
The survey should take approximately 15 minutes to complete. All responses go directly to researchers at the University of Nebraska Public Policy Center. DHHS will receive only a summary of aggregated results, no individual responses or identifying information will be collected or shared.
The survey will remain open until December 5. If you have any questions about the survey, please contact Quinn Lewandowski of the University of Nebraska Public Policy Center at qlewandowski2@nebraska.edu or 402-472-9459.
Also in Nebraska, the Department of Health and Human Services posted the draft minutes from the Drug Utilization Review (DUR) Board's October 28 meeting. The next meeting will be held on January 13, 2026.
Finally in Nebraska, the Department of Health and Human Services added the Buprenorphine: Practical Clinical Guidance for Prescribers under DUR Resources.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.
New York
The NYRx Education & Outreach team shared the following update.
Effective November 6, 2025, Rybelsus 3mg will be subject to the following clinical criteria:
- Prescriptions will be limited to a duration of 30 days, with no refills.
- Use for glycemic control will not be covered. System updates will be made to ensure alignment of coverage and criteria. Any claims that do not meet the criteria may be impacted and rejected at the pharmacy.
Any claims that do not meet criteria may be impacted and reject at the pharmacy.
The NYRx Education & Outreach Call Center is available by phone at 1-833-967-7310 or by email at NYRxEO@primetherapeutics.com from 8:00 am to 5:00 pm ET, Monday through Friday, excluding holidays.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.
For more information, contact NACDS’ Leigh Knotts at 803-243-7207.
For more information, please contact NACDS’ Mike Sargent at 207-272-6435.
For more information, contact NACDS’ Jill McCormack at 717-592-8977.
For more information, contact NACDS’ Mary Staples at 817-442-1155.
Ohio
Gov. Mike DeWine (R) announced that he is nominating Scott R. Partika to be the director of the Department of Medicaid, following the announcement that Director Maureen Cocoran is retiring. Partika's nomination must be confirmed by the Senate.
Also in Ohio, the Board of Pharmacy has posted the following:
For more information, contact NACDS’ Jill McCormack at 717-592-8977.
Oregon
The Prescription Drug Affordability Board (PDAB) posted its draft agenda for the November 19 meeting. Check the PDAB website for updates to the agenda and the meeting materials. Register in advance.
Also in Oregon, the Oregon Health Authority issued a notice of proposed rulemaking amending prior authorization criteria and preferred drug list to implement recommendations from the Drug Utilization Review / Pharmacy & Therapeutics action. A hearing is scheduled to be held on November 17 from 11:00 am – 11:45 am. See notice for details.
Finally in Oregon, the Office of Governor Tina Kotek and Oregon Health Authority's (OHA) Public Health Division are seeking applicants for one position (member at large) on the state Public Health Advisory Board (PHAB). Please refer to the announcement for more information.
OHA invites applicants from a wide range of backgrounds including pharmacists with experience in prevention, patient care or a public health issue. This term for this position is scheduled to begin January 1, 2026.
Learn about the application process here.
To apply, complete the electronic application process by November 30.
These recruitments will remain open until filled.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.
Wyoming
The state announced the submission of its application to CMS for the $50 billion Rural Health Transformation Program. The application outlines the state's plan to use the funding to address the biggest health challenges identified by rural Wyoming communities through 11 local town hall meetings and prioritized through an online survey with over 1,300 responses.
Also in Wyoming, Gov. Mark Gordon (R) recently issued Executive Order (2025-07) directing the Department of Family Services (DFS) to begin the process of submitting a waiver request to restrict the use of Supplemental Nutrition Assistance Program (SNAP) benefits for the purchase of certain foods that offer little or no nutritional value, such as sugary beverages and candy.
Finally in Wyoming, Gov. Mark Gordon (R) recently declared a Public Welfare Emergency and issued an Executive Order (2025-08) authorizing up to $10 million in state emergency funds to ensure Wyoming families continue to have access to food if federal Supplemental Nutrition Assistance Program (SNAP) dollars run out due to the federal government shutdown.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.
Alaska
NACDS is working collaboratively with the Alaska Pharmacy Association to ensure pharmacists and pharmacies are included in the Rural Health Transformation Program funding.
For more information, contact NACDS’ Mary Staples at 817-442-1155.
California
The Board of Pharmacy posted the following:
- Licensing Committee – October 15 agenda and meeting materials
- Enforcement & Compounding Committee – October 16 agenda
Also in California, the Department of Health Care Service posted the following on the Medi-Cal Rx Web Portal:
Also in California, the Board of Pharmacy issued a Notice of Third Modified Text – Discontinuance of Business – Updated. The Board of Pharmacy has proposed additional modifications to Title 16 CCR § 1708.2, related to the Discontinuance of Business.
Any person who wishes to comment on the proposed modifications may do so by submitting written comments beginning on October 6 and ending on October 22 to the following:
Contact Person: Debbie Damoth
Agency Name: California State Board of Pharmacy
Address: 2720 Gateway Oaks Drive, Ste. 100, Sacramento, CA 95833
Email: PharmacyRulemaking@dca.ca.gov
Fax: 916-574-8618
Please be advised the additional changes made to Title 16 CCR § 1708.2 reflect nonsubstantive changes with the exception of changes made to Title 16 CCR § 1708.2(b)(4). As a result, comments submitted should pertain only to the additional changes made to Title 16 CCR § 1708.2(b)(4). Any responses to comments directly concerning the proposed modifications to the text of the regulations will be considered and responded to in the Final Statement of Reasons.
Finally in California, the Board of Pharmacy posted this "Vaccine Alert".
Updated information on pharmacist authority to administer vaccines
The Board wishes to advise licensees about important upcoming changes to pharmacist authority related to vaccine administration enacted by Assembly Bill 1503 (Berman, Chapter 196, Statutes of 2025). AB 1503 was recently signed by Governor Newsom and will take effect on January 1, 2026. Under the provisions established in AB 1503, pharmacist authority to independently initiate and administer vaccines for persons three years of age and older will transition to a standard of care practice model. Such an approach is consistent with other health care practitioners with similar practice authority.
In anticipation of this change, the Board strongly encourages pharmacists to begin the transition to a standard of care practice model for immunizations for patients three years old and older. The Board intends to use enforcement discretion during this intervening period.
The Board also reminds pharmacists that Business and Professions Code section 4052(a)(11) currently provides a pharmacist with the authority to administer immunizations to any person, regardless of age, pursuant to a protocol with a prescriber. This current authority will exist until January 1, 2026, when AB 1503 takes effect.
Note that while AB 1503 repeals current subdivision (a)(11) of section 4052, it also adds new subdivision (a)(12), which, effective as of January 1, 2026, provides general authority for a pharmacist to initiate, adjust, or discontinue drug therapy for a patient (which includes vaccine administration) under either (1) a collaborative practice agreement, or (2) under specified conditions, an order or authorization made by the patient's prescriber. (See Stats. 2025, Ch. 196, Sec. 13 (AB 1503), effective January 1, 2026.)
Finally, as announced in a separate alert released on September 18, 2025, the Board reminds licensees about the following recent developments related to vaccines:
- In early September, the West Coast Health Alliance was launched to provide evidence-based unified recommendations for residents of California, Oregon, Washington, and Hawaii regarding who should receive immunizations.
- On September 17, the California Department of Public Health announced official immunization recommendations in accordance with this Alliance.
- Recent enactment of Assembly Bill 144 (Committee on Budget, Chapter 105, Statutes of 2025) provides authority for pharmacists to independently initiate and administer to individuals three years of age or older an immunization that, on January 1, 2025, had in effect an ACIP recommendation and that is recommended by the California Department of Public Health. This authority became effective on September 17, 2025, and provides separate and independent authority (complementing other current and forthcoming authorities) for pharmacists to administer vaccines.
- AB 144 also contains provisions related to Medi-Cal coverage of vaccines and immunizations. Learn more about Medi-Cal coverage of vaccines here.
Thank you for your commitment to California patients.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.
For more information, contact NACDS’ Leigh Knotts at 803-243-7207.
For more information, please contact NACDS’ Mike Sargent at 207-272-6435.
For more information, contact NACDS’ Jill McCormack at 717-592-8977.
For more information, contact NACDS’ Mary Staples at 817-442-1155.